|
|
|
|
Study participants (N=69)
|
Study participants (N=69)
|
Non-participants
(N=23), P-value3
|
Not approached
(N=14), P-value3
|
Child variables |
Child variables |
Child variables |
Child variables |
|
|
|
|
|
Male sex, N (%) |
Male sex, N (%) |
Male sex, N (%) |
47 (68%) |
47 (68%) |
14 (61%), P=.52 |
8 (57%),
P=.44 |
|
Age at assessment, mean years (SD) |
Age at assessment, mean years
(SD) |
Age at assessment, mean years (SD) |
11.6 (2.8) |
11.6 (2.8) |
11.1 (4.3), P=.76 |
9.9 (2.3), P=.08 |
|
Time since diagnosis, mean days (SD) |
Time since diagnosis, mean days
(SD) |
Time since diagnosis, mean days (SD) |
53 (28) |
53 (28) |
|
|
|
Body Mass Index, mean (SD) |
Body Mass Index, mean (SD) |
Body Mass
Index, mean (SD) |
18.7 (3.7) |
18.7 (3.7) |
|
|
|
Parental education level1
|
Parental education
level1
|
Parental education level1
|
|
|
|
|
|
|
Low-Middle N (%) |
Low-Middle N (%) |
33 (51%) |
33 (51%) |
|
|
|
|
High, N (%) |
High, N (%) |
32 (49%) |
32 (49%) |
|
|
Medical variables |
Medical variables |
Medical variables |
Medical
variables |
|
|
|
|
|
Tumor type |
Tumor type |
Tumor type |
|
|
|
|
|
|
Low grade glioma, N (%) |
Low grade glioma, N (%) |
33 (48%) |
33
(48%) |
|
|
|
|
Germ cell tumor, N (%) |
Germ cell tumor, N (%) |
10 (15%) |
10
(15%) |
|
|
|
|
Craniopharyngioma, N (%) |
Craniopharyngioma, N (%) |
9 (13%) |
9
(13%) |
|
|
|
|
High grade glioma, N (%) |
High grade glioma, N (%) |
6 (8%) |
6
(8%) |
|
|
|
|
Medulloblastoma, N (%) |
Medulloblastoma, N (%) |
6 (8%) |
6
(8%) |
|
|
|
|
Ependymoma, N (%) |
Ependymoma, N (%) |
2 (3%) |
2 (3%) |
|
|
|
|
Other, N (%)2
|
Other, N (%)2
|
3 (4%) |
3 (4%) |
|
|
|
Tumor location |
Tumor location |
Tumor location |
|
|
|
|
|
|
Posterior fossa, N (%) |
Posterior fossa, N (%) |
29 (42%) |
29
(42%) |
8 (35%), P=.54 |
6 (43%), P=.95 |
|
|
Supratentorial medial structures, N (%) |
Supratentorial medial
structures, N (%) |
26 (38%) |
26 (38%) |
5 (22%), P=.16 |
5
(36%), P=.89 |
|
|
Cerebral lobes, N (%) |
Cerebral lobes, N (%) |
14 (20%) |
14
(20%) |
10 (44%), P=.03* |
3 (21%),
P=.92 |
|
Started treatment |
Started treatment |
Started treatment |
|
|
|
|
|
|
Neurosurgery, N (%) |
Neurosurgery, N (%) |
63 (91%) |
63 (91%) |
|
|
|
|
Started chemotherapy, N (%) |
Started chemotherapy, N (%) |
12
(17%) |
12 (17%) |
|
|
|
|
Started radiotherapy, N (%) |
Started radiotherapy, N (%) |
13
(19%) |
13 (19%) |
|
|
|
|
|
Proton therapy, N (%) |
5 (7%) |
5 (7%) |
|
|
|
|
|
Photon therapy, N (%) |
8 (12%) |
8 (12%) |
|
|
|
|
Obstructive hydrocephalus, N (%) |
Obstructive hydrocephalus, N
(%) |
33 (48%) |
33 (48%) |
|
|
|
|
Hormone deficiency, N (%) |
Hormone deficiency, N (%) |
18 (26%) |
18 (26%) |
|
|
|
|
Epilepsy, N (%) |
Epilepsy, N (%) |
9 (13%) |
9 (13%) |
|
|